|
1
|
Gupta S, Maheshwari A, Parab P,
Mahantshetty U, Hawaldar R, Sastri Chopra S, Kerkar R, Engineer R,
Tongaonkar H, Ghosh J, et al: Neoadjuvant chemotherapy followed by
radical surgery versus concomitant chemotherapy and radiotherapy in
patients with stage IB2, IIA, or IIB squamous cervical cancer: A
randomized controlled trial. J Clin Oncol. 36:1548–1555. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morris M, Eifel PJ, Lu J, Grigsby PW,
Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG:
Pelvic radiation with concurrent chemotherapy compared with pelvic
and para-aortic radiation for high-risk cervical cancer. N Engl J
Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Keys HM, Bundy BN, Stehman FB, Muderspach
LI, Chafe WE, Suggs CL III, Walker JL and Gersell D: Cisplatin,
radiation, and adjuvant hysterectomy compared with radiation and
adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl
J Med. 340:1154–1161. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rose PG, Bundy BN, Watkins EB, Thigpen JT,
Deppe G, Maiman MA, Clarke-Pearson DL and Insalaco S: Concurrent
cisplatin-based radiotherapy and chemotherapy for locally advanced
cervical cancer. N Engl J Med. 340:1144–1153. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ishiko O, Sumi T, Yasui T, Matsumoto Y,
Kawamura N, Ogita S, Kamino T, Nakamura K and Yamada R:
Balloon-occluded arterial infusion chemotherapy, simple total
hysterectomy, and radiotherapy as a useful combination-therapy for
advanced cancer of the uterine cervix. Oncol Rep. 7:141–144.
2000.PubMed/NCBI
|
|
6
|
Kawaguchi R, Nakamura H, Morioka S, Ito H,
Tanase Y, Haruta S, Kanayama S, Yosida S, Furukawa N, Oi H and
Kobayashi H: Comparison of neoadjuvant intraarterial chemotherapy
versus concurrent chemoradiotherapy in patients with stage IIIB
uterine cervical cancer. World J Oncol. 4:221–229. 2013.PubMed/NCBI
|
|
7
|
Chen H, Liang C, Zhang L, Huang S and Wu
X: Clinical efficacy of modified preoperative neoadjuvant
chemotherapy in the treatment of locally advanced (stage IB2 to
IIB) cervical cancer: Randomized study. Gynecol Oncol. 110:308–315.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Souhami L, Gil RA, Allan SE, Canary PC,
Araújo CM, Pinto LH and Silveira TR: A randomized trial of
chemotherapy followed by pelvic radiation therapy in stage IIIB
carcinoma of the cervix. J Clin Oncol. 9:970–977. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tattersall MH, Lorvidhaya V, Vootiprux V,
Cheirsilpa A, Wong F, Azhar T, Lee HP, Kang SB, Manalo A, Yen MS,
et al: Randomized trial of epirubicin and cisplatin chemotherapy
followed by pelvic radiation in locally advanced cervical cancer.
Cervical cancer study group of the Asian Oceanian clinical oncology
association. J Clin Oncol. 13:444–451. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de la Torre M: Neoadjuvant chemotherapy in
woman with early or locally advanced cervical cancer. Rep Pract
Oncol Radiother. 23:528–532. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamauchi M, Fukuda T, Wada T, Kawanishi M,
Imai K, Tasaka R, Yasui T and Sumi T: Expression of epidermal
growth factor-like domain 7 may be a predictive marker of the
effect of neoadjuvant chemotherapy for locally advanced uterine
cervical cancer. Oncol Lett. 12:5183–5189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Imai K, Fukuda T, Wada T, Kawanishi M,
Tasaka R, Yasui T and Sumi T: UCP2 expression may represent a
predictive marker of neoadjuvant chemotherapy effectiveness for
locally advanced uterine cervical cancer. Oncol Lett. 14:951–957.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okamoto E, Sumi T, Misugi F, Nobeyama H,
Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K and Ishiko O:
Expression of apoptosis-related proteins in advanced uterine
cervical cancer after balloon-occluded arterial infusion
chemotherapy as an indicator of the efficiency of this therapy. Int
J Mol Med. 15:41–47. 2005.PubMed/NCBI
|
|
14
|
Nobeyama H, Sumi T, Misugi F, Okamoto E,
Hattori K, Matsumoto Y, Yasui T, Honda K, Iwai K and Ishiko O:
Association of HPV infection with prognosis after neoadjuvant
chemotherapy in advanced uterine cervical cancer. Int J Mol Med.
14:101–105. 2004.PubMed/NCBI
|
|
15
|
Benedetti Panici P, Bellati F, Manci N,
Pernice M, Plotti F, Di Donato V, Calcagno M, Zullo MA, Muzii L and
Angioli R: Neoadjuvant chemotherapy followed by radical surgery in
patients affected by FIGO stage IVA cervical cancer. Ann Surg
Oncol. 14:2643–2648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karakashev SV and Reginato MJ: Progress
toward overcoming hypoxia-induced resistance to solid tumor
therapy. Cancer Manag Res 7: 253-264, 2015. Graham K and Unger E:
Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy
and immunotherapy in cancer treatment. Int J Nanomedicine.
13:6049–6058. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Balamurugan K: HIF-1 at the crossroads of
hypoxia, inflammation, and cancer. Int J Cancer. 138:1058–1066.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jaakkola P, Mole DR, Tian YM, Wilson MI,
Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji
M, Schofield CJ, et al: Targeting of HIF-alpha to the von
Hippel-Lindau ubiquitylation complex by O2-regulated prolyl
hydroxylation. Science. 292:468–472. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin SC, Chien CW, Lee JC, Yeh YC, Hsu KF,
Lai YY, Lin SC and Tsai SJ: Suppression of dual-specificity
phosphatase-2 by hypoxia increases chemoresistance and malignancy
in human cancer cells. J Clin Invest. 121:1905–1916. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Q, Tian WJ, Huang ML, Liu CH, Yao TT
and Guan MM: Association between HIF-1 alpha gene polymorphisms and
response in patients undergoing neoadjuvant chemotherapy for
locally advanced cervical cancer. Med Sci Monit. 22:3140–3146.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Semenza GL: Defining the role of
hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 29:625–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brown JM and Wilson WR: Exploiting tumour
hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iwasaki K, Yabushita H, Ueno T and
Wakatsuki A: Role of hypoxia-inducible factor-1α, carbonic
anhydrase-IX, glucose transporter-1 and vascular endothelial growth
factor associated with lymph node metastasis and recurrence in
patients with locally advanced cervical cancer. Oncol Lett.
10:1970–1978. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim BW, Cho H, Chung JY, Conway C, Ylaya
K, Kim JH and Hewitt SM: Prognostic assessment of hypoxia and
metabolic markers in cervical cancer using automated digital image
analysis of immunohistochemistry. J Transl Med. 11:1852013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang M, Chen Q, Xiao J, Yao T, Bian L,
Liu C and Lin Z: Overexpression of hypoxia-inducible factor-1α is a
predictor of poor prognosis in cervical cancer: A clinicopathologic
study and a meta-analysis. Int J Gynecol Cancer. 24:1054–1064.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsui Y, Kanoh H, Okudaira Y, Hashimoto T
and Nakamura H: Superselective
transcatheter-arterial-chemo-embolization in uterine cervical
cancer. Gan To Kagaku Ryoho. 16:2801–2804. 1989.(In Japanese).
PubMed/NCBI
|
|
27
|
Tsuji K, Yamada R, Kawabata M, Mitsuzane
K, Sato M, Iwahashi M, Kitayama S and Nakano R: Effect of balloon
occluded arterial infusion of anticancer drugs on the prognosis of
cervical cancer treated with radiation therapy. Int J Radiat Oncol
Biol Phys. 32:1337–1345. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
World Health Handbook for reporting
results of cancer treatment. World Health Organization. (Geneva,
Offset Publication, No. 48). 1989.
|
|
29
|
Yan B, Wei JJ, Yuan Y, Sun R, Li D, Luo J,
Liao SJ, Zhou YH, Shu Y, Wang Q, et al: IL-6 cooperates with G-CSF
to induce protumor function of neutrophils in bone marrow by
enhancing STAT3 activation. J Immunol. 190:5882–5893. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
31
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology-Cervical
Cancer-Version II. 2013.
|
|
32
|
Angioli R, Luvero D, Aloisi A, Capriglione
S, Gennari P, Linciano F, Li Destri M, Scaletta G, Montera R and
Plotti F: Adjuvant chemotherapy after primary treatments for
cervical cancer: A critical point of view and review of the
literature. Expert Rev Anticancer Ther. 14:431–439. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wada T, Fukuda T, Shimomura M, Inoue Y,
Kawanishi M, Tasaka R, Yasui T, Ikeda K and Sumi T: XPA expression
is a predictive marker of the effectiveness of neoadjuvant
chemotherapy for locally advanced uterine cervical cancer. Oncol
Lett. 15:3766–3771. 2018.PubMed/NCBI
|
|
34
|
Ditto A, Martinelli F, Borreani C,
Kusamura S, Hanozet F, Brunelli C, Rossi G, Solima E, Fontanelli R,
Zanaboni F, et al: Quality of life and sexual, bladder, and
intestinal dysfunctions after class III nerve-sparing and class II
radical hysterectomies: A questionnaire-based study. Int J Gynecol
Cancer. 19:953–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Robova H, Halaska M, Pluta M, Skapa P,
Strnad P, Lisy J and Rob L: The role of neoadjuvant chemotherapy
and surgery in cervical cancer. Int J Gynecol Cancer. 20 (11 Suppl
2):S42–S46. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iwata T, Miyauchi A, Suga Y, Nishio H,
Nakamura M, Ohno A, Hirao N, Morisada T, Tanaka K, Ueyama H, et al:
Neoadjuvant chemotherapy for locally advanced cervical cancer. Chin
J Cancer Res. 28:235–240. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Landoni F, Sartori E, Maggino T, Zola P,
Zanagnolo V, Cosio S, Ferrari F, Piovano E and Gadducci A: Is there
a role for postoperative treatment in patients with stage Ib2-IIb
cervical cancer treated with neo-adjuvant chemotherapy and radical
surgery? An Italian multicenter retrospective study. Gynecol Oncol.
132:611–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Minig L, Colombo N, Zanagnolo V, Landoni
F, Bocciolone L, Cárdenas-Rebollo JM, Iodice S and Maggioni A:
Platinum-based neoadjuvant chemotherapy followed by radical surgery
for cervical carcinoma international federation of gynecology and
obstetrics stage IB2-IIB. Int J Gynecol Cancer. 23:1647–1654. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Semenza GL: HIF-1: Upstream and downstream
of cancer metabolism. Curr Opin Genet Dev. 20:51–56. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci
USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Seeber LM, Horrée N, Vooijs MA, Heintz AP,
van der Wall E, Verheijen RH and van Diest PJ: The role of hypoxia
inducible factor-1alpha in gynecological cancer. Crit Rev Oncol
Hematol. 78:173–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Łuczak MW, Roszak A, Pawlik P, Kędzia H,
Lianeri M and Jagodziński PP: Increased expression of HIF-1A and
its implication in the hypoxia pathway in primary advanced cervical
carcinoma. Oncol Rep. 26:1259–1264. 2011.PubMed/NCBI
|
|
43
|
Masoud GN and Li W: HIF-1α pathway: Role,
regulation and intervention for cancer therapy. Acta Pharm Sin B.
5:378–389. 2015. View Article : Google Scholar : PubMed/NCBI
|
